[go: up one dir, main page]

BRPI1011902A2 - composições e métodos para potencialização de respostas imunes antígeno-específicas - Google Patents

composições e métodos para potencialização de respostas imunes antígeno-específicas

Info

Publication number
BRPI1011902A2
BRPI1011902A2 BRPI1011902A BRPI1011902A BRPI1011902A2 BR PI1011902 A2 BRPI1011902 A2 BR PI1011902A2 BR PI1011902 A BRPI1011902 A BR PI1011902A BR PI1011902 A BRPI1011902 A BR PI1011902A BR PI1011902 A2 BRPI1011902 A2 BR PI1011902A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
immune responses
specific immune
enhancing antigen
Prior art date
Application number
BRPI1011902A
Other languages
English (en)
Inventor
Hung Chien-Fu
Wu Tzyy-Choou
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of BRPI1011902A2 publication Critical patent/BRPI1011902A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI1011902A 2009-04-28 2010-04-28 composições e métodos para potencialização de respostas imunes antígeno-específicas BRPI1011902A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17341309P 2009-04-28 2009-04-28
PCT/US2010/032779 WO2010129339A2 (en) 2009-04-28 2010-04-28 Compositions and methods for enhancing antigen-specific immune responses

Publications (1)

Publication Number Publication Date
BRPI1011902A2 true BRPI1011902A2 (pt) 2019-09-24

Family

ID=43050757

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011902A BRPI1011902A2 (pt) 2009-04-28 2010-04-28 composições e métodos para potencialização de respostas imunes antígeno-específicas

Country Status (7)

Country Link
US (1) US20120244173A1 (pt)
EP (1) EP2424990A4 (pt)
JP (2) JP5690814B2 (pt)
AU (1) AU2010246273B2 (pt)
BR (1) BRPI1011902A2 (pt)
CA (1) CA2760310A1 (pt)
WO (1) WO2010129339A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
WO2004098526A2 (en) 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
CN110042110A (zh) 2012-01-24 2019-07-23 桑福德健康公司 用于治疗致癌病毒多肽阳性肿瘤的多核苷酸
JP2016513115A (ja) 2013-02-21 2016-05-12 チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド ワクチン組成物
JP6554095B2 (ja) 2013-06-25 2019-07-31 アエラス グローバル ティービー ワクチン ファウンデーション 結核組成物及びそれを使用する方法
EP3094652B1 (en) 2014-01-13 2021-09-29 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
WO2016025295A1 (en) * 2014-08-06 2016-02-18 The Johns Hopkins University Compositions and methods for enhancing antigen-specific immune responses
CA3027995A1 (en) 2016-06-16 2017-12-21 Aeras Tuberculosis compositions and methods of treating or preventing tuberculosis
AU2018299884A1 (en) * 2017-07-10 2019-12-19 Dana-Farber Cancer Institute, Inc. Identification and use of cytotoxic T lymphocyte (CTL) antigen-specific target cell killing enhancer agents
US20210388390A1 (en) * 2018-10-04 2021-12-16 Sqz Biotechnologies Company Intracellular delivery of biomolecules to enhance antigen presenting cell function
US20220184158A1 (en) * 2018-12-21 2022-06-16 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
WO2021119623A1 (en) * 2019-12-13 2021-06-17 Northwestern University Method and composition for enhancing the immune response

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT97073A (pt) * 1990-03-20 1991-10-31 Behringwerke Ag Processo para a preparacao de epitopos soro-reactivos de proteinas de papillomavirus 16 humano (hpv)
EP1572090A4 (en) * 2002-06-27 2006-11-15 Geron Corp CANCER VACCINE WITH CROSS-SPEED EPITOPES OF THE TELOMERASE REVERSE TRANSCRIPTASE
EP1890724A2 (en) * 2005-05-13 2008-02-27 Oxxon Therapeutics Limited Compositions for inducing an immune response
EP1968629A2 (en) * 2005-12-21 2008-09-17 Glaxo Group Limited Method of eliciting immune response
WO2009007336A1 (en) * 2007-07-06 2009-01-15 Genimmune N.V. Methods for generating an immune response using dna and a viral vector

Also Published As

Publication number Publication date
AU2010246273B2 (en) 2014-04-03
US20120244173A1 (en) 2012-09-27
CA2760310A1 (en) 2010-11-11
JP2012525410A (ja) 2012-10-22
EP2424990A4 (en) 2013-05-15
WO2010129339A3 (en) 2011-03-03
EP2424990A2 (en) 2012-03-07
JP2015017117A (ja) 2015-01-29
WO2010129339A2 (en) 2010-11-11
AU2010246273A1 (en) 2011-12-01
JP5690814B2 (ja) 2015-03-25

Similar Documents

Publication Publication Date Title
BRPI1011902A2 (pt) composições e métodos para potencialização de respostas imunes antígeno-específicas
BRPI0920283A2 (pt) composição e método para induzir resposta imunológica humoral
BRPI0920282A2 (pt) composição e método para induzir resposta imunológica humoral
SMT201600049B (it) Formulazioni di apixaban
IL224390B (en) Compositions and methods for targeted thermal modulation
BR112012031446A2 (pt) componentes e métodos para implantes
BRPI1012525A2 (pt) composições de nanopatículas isentas de príons e métodos para sua fabricação
PT2734049T (pt) Composições e métodos probióticos
HUE039747T2 (hu) Eljárások és kompozíciók EGFRVIII-ra való immunválasz indukálására
HUE031343T2 (hu) Immunitásindukáló ágens
DK3023106T3 (da) Mycobacterium-antigensammensætning
PT2512502T (pt) Métodos e composições para supressão de tumores
EP2598120A4 (en) COMPOSITIONS AND METHOD FOR CREATING AN IMMUNO TOLERANCE
BRPI1008326A2 (pt) Composições e métodos para controlar nanatódeos
WO2011017162A9 (en) Methods for enhancing antigen-specific immune responses
LT2654785T (lt) Sustiprintas galvijų imuninis atsakas
BR112013003676A2 (pt) composições de alimentos funcionais e métodos
BR112013012988A2 (pt) dispositivo de preparação de bebidas e método de preparação de uma bebida
BR112013012583A2 (pt) composições de limpeza diluíveis e métodos para utilização
BR112014010769A2 (pt) métodos e composições para neuroproteção
BR112013008026A2 (pt) composições que compreendem ligantes sintéticos multivalentes de nucleolina de superfície e glicosaminaglicanos
BR112012029669A2 (pt) composição e método
BR112013019707A2 (pt) métodos e composições antinematóides
BR112013008812A2 (pt) composição e método
DK2438082T3 (da) Rekombinant-fremstillede allergener

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.